A Delaware district court ruled that Sanofi and Regeneron Pharmaceuticals Inc. infringed the patents that competitor Amgen holds for its PCSK9 inhibitor, Repatha.
The decision blocks Sanofi and Regeneron from selling their drug Praluent in the United States. The injunction has been delayed for 30 days to allow the companies time to appeal, which they intend to do.
Amgen’s share rose close to 4 percent in after-hours trading on Thursday, according to Yahoo Finance.
Read the full story